THE APEX TIMES
Eli Lilly agrees to pay up to $3.8 billion to access AtaiBeckley’s psychedelic nasal spray
The deal would give Eli Lilly rights to a psychedelic-based, single-dose nasal spray being studied for treatment-resistant depression, as Big Pharma deepens its search for faster-acting mental health treatments.
Eli Lilly is set to pay up to $3.8 billion for access to AtaiBeckley’s psychedelic-based nasal spray, according to a report published by Yahoo Finance and re-circulated by The Daily Upside. The arrangement reflects how major drug companies are continuing to broaden beyond traditional antidepressants and toward therapies that may act on depression in different ways.
At the center of the deal is a nasal spray formulation tied to psychedelic research. The report says studies indicate it can curb treatment-resistant depression in a single dose, a potentially important distinction because treatment-resistant depression is a subtype in which many patients do not respond to standard therapies.
For Lilly, expanding a pipeline into mental health is an ongoing strategic need, and the company has repeatedly targeted areas where it believes it can translate scientific advances into meaningful clinical outcomes. A single-dose approach, if it holds up in additional data, could also change how clinics think about dosing logistics and timelines for patients who have not found relief elsewhere.
The headline number in the report is $3.8 billion, framed as the maximum amount Lilly would pay. Deals structured around milestones or conditional payments are common in pharma licensing and collaboration agreements, but the report does not provide details on the payment structure, including how much is due upfront, what triggers additional payments, or whether any commercial royalties are involved.
AtaiBeckley, the counterparty in the report, is described in this coverage in connection with the nasal spray program. However, the available information does not spell out AtaiBeckley’s broader portfolio, Lilly’s specific rights (for example, geography or indications beyond treatment-resistant depression), or whether Lilly would be responsible for late-stage development and manufacturing.
Broader interest in psychedelics has gathered momentum in recent years, especially for difficult-to-treat conditions. The attraction for established drug makers is not just the novelty of the mechanism, but the possibility of differentiated efficacy indicates and a path to address areas of unmet medical need. Still, psychedelic-adjacent development also comes with regulatory scrutiny and operational questions around clinical protocols and patient eligibility.
The report does not disclose which phase of clinical testing the nasal spray has reached, what the study size was, or the nature of the efficacy measurements used to define “curbs” treatment-resistant depression. It also does not provide safety findings, duration of response beyond the immediate effect, or data about side effects that could affect adoption in real-world settings.
What to watch next is whether Lilly and AtaiBeckley publish more granular trial results and whether regulatory filings or investor materials clarify the structure of the $3.8 billion figure. Investors and clinicians will also be looking for confirmation that the single-dose effect is durable, reproducible across patient subgroups, and supported by safety and tolerability data sufficient to advance the program.
Why It Matters
- The deal indicates renewed Big Pharma interest in psychedelic-based mental health therapies, particularly for hard-to-treat depression.
- A single-dose approach, if validated, could differentiate the program from standard antidepressant regimens that often require longer timelines.
- Milestone-heavy payments, common in pharma deals, can shift risk and reward between partners depending on clinical and regulatory outcomes.
- The lack of published trial details in the immediate reporting means the magnitude and durability of the effect remain to be independently assessed as more data emerge.
Key Facts
- Eli Lilly agreed to pay up to $3.8 billion to gain access to AtaiBeckley’s psychedelic-based nasal spray.
- The nasal spray is being studied for treatment-resistant depression.
- The report characterizes the therapy as having an effect after a single dose in studies.
- The coverage does not provide a payment breakdown or specific milestones tied to the maximum amount.
Healthcare Related
Lilly’s $2.88 Billion Immunology Acquisition Moves Into Phase 1 as Lead Program Remains Early
Eli Lilly says a milestone-based immunology deal that adds a broader scientific platform has begun a Phase 1 study, but its lead medicine is still at the earliest clinical stage, underscoring the execution risk common to early-stage pipeline builds.
Eli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fit
The U.S. drugmaker said it will acquire Merida Biosciences in a transaction valued at $2.88 billion, a move that is drawing attention to how Lilly is expanding its pipeline and capabilities.
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.